FDA warned Dallas peptide seller TXP Innovations (Tex Peptides) that its website sells unapproved injectable drugs, including semaglutide and tirzepatide.
What happened
FDA reviewed the website texpeptide.com in July 2026 rather than doing an inspection. The review found seven products marketed with drug claims, such as treating type 2 diabetes, obesity, weight loss and libido, with no FDA-approved application. FDA also noted the company sells bacteriostatic water alongside the peptides so buyers can reconstitute them for injection.
What FDA found
The company sells these peptides as drugs without any FDA-approved application, which is illegal for a new drug.
Section 505(a), FD&C Act, 21 U.S.C. 355(a)Website text says the products treat diseases and change body functions such as blood sugar, weight and hormone levels, which makes them drugs.
Section 201(g)(1), FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128The products are not generally recognized as safe and effective for the uses described in their labeling, so they are 'new drugs'.
Section 201(p), FD&C Act, 21 U.S.C. 321(p)Shipping these unapproved drugs across state lines breaks the law.
Sections 301(d) and 505(a), FD&C Act, 21 U.S.C. 331(d) and 355(a)Selling bacteriostatic water next to the peptides shows it is meant to be used to prepare them for injection, so the water is a drug too.
Section 201(g)(1), FD&C Act, 21 U.S.C. 321(g)(1)Labels saying 'research use only' and 'not for human use' do not cancel out the drug claims and the injectable-water sales, which show the products are meant for people.
21 CFR 201.128
What FDA wants
FDA tells the company to investigate the root causes, fix the violations and write to FDAAdvisory@fda.hhs.gov within 15 business days with the steps taken, how it will prevent repeat violations, and supporting documents, citing reference 735067.
Who should pay attention
- online peptide and 'research chemical' sellers
- brands and clinics that buy peptides from online suppliers
- compounding pharmacies and telehealth sellers of GLP-1 products
This is a summary. Read the original letter on fda.gov.